News - Genmab, Johnson & Johnson


Current filters:

GenmabJohnson & Johnson

Popular Filters

Janssen and Genmab's daratumumab fast-tracked by US FDA


Denmark-based biotech firm Genmab A/S (OMX: GEN) says that the US Food and Drug Administration has granted…

BiotechnologydaratumumabGenmabJanssen BiotechJohnson & JohnsonNorth AmericaOncologyRegulation

Genmab leaps on $1.1 billion daratumumab deal with Janssen


Denmark's Genmab A/S (OMX: GEN) saw its shares leap 20% to 81 Danish kroner in morning trading yesterday,…

BiotechnologydaratumumabFinancialGenmabHuMax-CD38JanssenJohnson & JohnsonLicensingOncologyPharmaceutical

Genmab in collaboration with Janssen for DuoBody platform


Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

Back to top